- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07241546
Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
A Randomized, Double-blind, Placebo-controlled Phase 2a Study of ARO-RAGE Inhalation Solution to Assess Efficacy on Small Airway Dysfunction in Allergen-induced Mild Asthma
The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Medical Monitor
- Phone Number: 626-304-3400
- Email: ARORAGE-2001@arrowheadpharma.com
Study Locations
-
-
-
Calgary, Canada, T2N 4N1
- Recruiting
- Research Site 2
-
Edmonton, Canada, T6G 2G3
- Recruiting
- Research Site 3
-
Hamilton, Canada, L8N 3Z5
- Recruiting
- Research Site 5
-
Québec, Canada, G1V-4G5
- Recruiting
- Research Site 6
-
Saskatoon, Canada, S7M 2W2
- Recruiting
- Research Site 4
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Recruiting
- Research Site 1
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinically stable, mild atopic asthma (FEV1 ≥70% predicted)
- Established allergy confirmed by positive skin prick test at screening
- Willing and able to perform lung function tests and other study-related procedures
- Participants of childbearing potential must consent to use a method of highly-effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last investigational product administration, whichever is later
Exclusion Criteria:
- Concomitant diagnosis of a clinically important pulmonary disease other than asthma
- Use of corticosteroids, immunosuppressives, or anti-inflammatory medications that interfere with inhaled challenges or inflammation, or chronic use of any other medication for treatment of allergic asthma
- History or current medical condition contraindicating methacholine challenge
Note: Additional inclusion/exclusion criteria may apply per protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: ARO-RAGE
ARO-RAGE inhalation |
Inhalation of nebulized solution |
|
Placebo Comparator: Placebo
Normal saline (0.9%) |
Calculated volume to match active treatment by inhalation of nebulized solution |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from Baseline Over Time in Maximum Area of Reactance
Time Frame: Baseline through Day 58
|
Baseline through Day 58
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from Baseline Over Time in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve
Time Frame: Baseline through Day 58
|
Baseline through Day 58
|
|
Change from Baseline Over Time in Maximum Change in Small Airway Reactance
Time Frame: Baseline through Day 58
|
Baseline through Day 58
|
|
Number of Participants with Treatment-Emergent Adverse Events
Time Frame: Up to Day 113 (End of Study)
|
Up to Day 113 (End of Study)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ARORAGE-2001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.